secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kura Oncology, Inc. (KURA)
CIK:        0001422143
Form:       8-K
Filed at:   2024-05-24T23:59:59+00:00
Accession:  0001193125-24-147030
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Kura Oncology completes enrollment of 85 patients in Phase 2 KOMET-001 trial; topline data expected early 2025
--------------------------------------------------------------------------------

- Final enrollment of 85 patients in Phase 2 registration-directed trial of menin inhibitor ziftomenib for NPM1-mutant AML.
- Topline data from KOMET-001 trial expected in early 2025.
- Trial targets relapsed/refractory NPM1-mutant acute myeloid leukemia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422143/000119312524147030/0001193125-24-147030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422143/000119312524147030/d842527d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-147030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer